George Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK tablets in the US
George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, has entered into an exclusive licensing and supply agreement with Azurity Pharmaceuticals, a privately held global pharmaceutical company committed to delivering innovative, high-quality medicines for overlooked patients, granting Azurity exclusive rights to commercialize WIDAPLIK in the United States.
Health Technology Insights: Waters and Becton Dickinson Biosciences Diagnostic Solutions to Merge in $17.5 Billion Deal
WIDAPLIK is indicated for the treatment of hypertension, including as initial treatment, to lower blood pressure. It is a proprietary single pill combination of three medicines: telmisartan, amlodipine and indapamide and is available in three doses (10/1.25/0.625 mg, 20/2.5/1.25 mg, and 40/5/2.5 mg strengths), including two doses that are lower than those currently available in single pill combinations. It is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. WIDAPLIK, with its three different doses, can deliver the efficacy benefits of a triple mechanism approach early in the treatment pathway with an established safety profile.
WIDAPLIK carries a Boxed Warning for fetal toxicity and should be discontinued as soon as pregnancy is detected. Please see full Prescribing Information and Important Safety Information, including Boxed Warning for WIDAPLIK here.
Azurity is granted a license to exclusively commercialize WIDAPLIK, supplied by George Medicines, in the U.S. in return for milestone and royalty payments. Citibank acted as transaction advisor to George Medicines.
Azurity’s commercialization of WIDAPLIK is expected to commence in Q4 2025.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup
Mark Mallon, Chief Executive Officer of George Medicines, said: “This second major licensing and supply agreement, following the agreement established with Bausch Health in January 2025, further signals the substantial momentum for this triple combination therapy and our commitment to bring this medicine to patients in need around the world. Hypertension remains one of the most persistent public health challenges in the United States, with only one in four adults with the condition having their blood pressure under control. Our agreement with Azurity marks a pivotal step in George Medicines’ commitment to address the unmet needs in hypertension management and improve outcomes for patients across the United States of America.”
Ronald Scarboro, CEO, Azurity Pharmaceuticals, said: “This collaboration supports Azurity’s commitment to bringing highly differentiated products to patients with unmet needs. WIDAPLIK is a novel fixed-dose combination designed to simplify hypertension management for patients likely to require multiple therapies. It is a great fit for our cardiovascular portfolio and unique commercialization capabilities. We are pleased to bring this newly approved treatment option to patients in the US.”
Health Technology Insights: Viome and Scripps Research Partner to Create First At-Home RNA Test for Colon Cancer Prevention
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- GlobeNewswire
